Healthcare & Insurance
Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary
ORION CORPORATION STOCK EXCHANGE RELEASE 24 OCTOBER 2018 AT 8.30 a.m. EEST Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met Orion and
Wednesday, October 24, 2018
SCOR: First Nine Months 2018 Results
Press Release October 24, 2018 - N° 25 First Nine Months 2018 Results SCOR delivers very solid performance in the first nine months of 2018, with net income of EUR 342 million andnormalized1 net income of EUR 405 million The first nine months of 2018 fully demonstrate the
Wednesday, October 24, 2018
ISS and Glass Lewis recommend ICC Shareholders vote FOR Arrangement with Aurora Cannabis
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (the Company or ICC) (TSX-V: ICC) is pleased to announce that Institutional Shareholder Services Inc. (ISS) and Glass Lewis & Co. (Glass Lewis) have both favourably recommended that ICC Shareholders (defined below)
Wednesday, October 24, 2018
AmTrust Financial Services, Inc. Settlement Election Notice
5.50% Convertible Senior Notes Due 2021 NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- AmTrust Financial Services, Inc. (Nasdaq: AFSI) (“AmTrust” or the “Company”) today provided a settlement election notice to all holders of its 5.50% Convertible Senior Notes Due 2021 (the “Notes”)
Wednesday, October 24, 2018
Lexington Provides Q3 Corporate Review
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to review activities undertaken during Q3 of 2018. Over the summer, the Company
Tuesday, October 23, 2018
Psychemedics Announces Quarterly Results
Declares 89th Consecutive Quarterly Dividend ACTON, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2018. The Company also announced a quarterly dividend of $0.18 per share
Tuesday, October 23, 2018
BioCryst to Report Third Quarter 2018 Financial Results on November 6
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2018 financial results on Tuesday, November 6, 2018. BioCryst management will host a conference call and webcast at 8:30
Tuesday, October 23, 2018
Cutera, Inc. to Announce Third Quarter 2018 Results
BRISBANE, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, will announce financial results for the third quarter on Tuesday, November 6th,
Tuesday, October 23, 2018
SeaSpine to Report Third Quarter 2018 Financial Results on November 6, 2018
CARLSBAD, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release third quarter 2018 financial results after the close of
Tuesday, October 23, 2018
Sientra® to Release Third Quarter 2018 Financial Results on November 6, 2018
SANTA BARBARA, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release its third quarter 2018 financial results on Tuesday, November 6, 2018 after market close. Sientra
Tuesday, October 23, 2018
LogicBio Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need, today announced the closing of its initial public offering of
Tuesday, October 23, 2018
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results
Updated Regulatory Strategy Based on 12-Week Flare-up Data from Completed Phase 2 Program and Consultation with the FDA NDA Submission Planned for the Second Half of 2019 MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage
Tuesday, October 23, 2018
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Topline efficacy and safety results anticipated by early April 2019 MENLO PARK, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new
Tuesday, October 23, 2018
Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option
PITTSBURGH, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has closed the previously
Tuesday, October 23, 2018
HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility
HTG’s extraction-free, targeted next-generation sequencing technology adopted to support the IOR’s research and clinical trials in hematological cancers and solid tumors TUCSON, Ariz., Oct. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (“HTG”), a provider of
Tuesday, October 23, 2018
Greenlight Capital Re Schedules Third Quarter 2018 Financial Results and Conference Call
GRAND CAYMAN, Cayman Islands, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Greenlight Capital Re, Ltd. (NASDAQ: GLRE), a specialist property and casualty reinsurer based in the Cayman Islands and Ireland, today announced that it expects to release financial results for the third quarter ended September 30,
Tuesday, October 23, 2018
iCAD Announces New Clinical Data on the Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment Demonstrating Positive Results
Multi-center research presented at ASTRO 2018 shows IORT with the Xoft System is safe with low recurrence and low morbidity in the treatment of breast cancer Company marks 20 years of innovations in targeted cancer care at the conference NASHUA, N.H. and SAN ANTONIO, Oct. 23, 2018 (GLOBE
Tuesday, October 23, 2018
EUROBIO SCIENTIFIC CERTIFIED ISO 13485 V2016
EUROBIO SCIENTIFIC CERTIFIED ISO 13485 V2016 Eurobio Scientific has successfully upgraded its quality management systems in order to continue justifying CE marking of its products beyond 2019 Paris, October 23, 2018 - 5.45 pm Eurobio Scientific (FR0013240934, ALERS,
Tuesday, October 23, 2018
Transactions in relation to share buyback program
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on market abuse and the delegated regulation (EU) no. 2016/1052 of 8 March 2016,
Tuesday, October 23, 2018
Tabula Rasa Healthcare to Announce Third Quarter 2018 Operating Results and Host Conference Call on Tuesday, November 6, 2018
MOORESTOWN, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety, will release its third quarter 2018 operating results on Tuesday, November 6, 2018 after market close, on the investor
Tuesday, October 23, 2018
